Preventing and treating kidney disease in patients with type 2 diabetes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preventing and treating kidney disease in patients with type 2 diabetes
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 20, Issue 3, Pages 277-294
Publisher
Informa UK Limited
Online
2018-11-25
DOI
10.1080/14656566.2018.1551362
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Glycemic Control as Primary Prevention for Diabetic Kidney Disease
- (2018) Richard J. MacIsaac et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- The Global Epidemiology of Diabetes and Kidney Disease
- (2018) Digsu N. Koye et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition
- (2018) Vikram Patney et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review
- (2018) Radica Z. Alicic et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New
- (2018) Ronald M. Goldenberg et al. Canadian Journal of Diabetes
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- SGLT2 inhibition and kidney protection
- (2018) Josselin Nespoux et al. CLINICAL SCIENCE
- Type 2 Diabetes and Thiazide Diuretics
- (2018) André J. Scheen Current Diabetes Reports
- Reevaluating the Evidence for Blood Pressure Targets in Type 2 Diabetes
- (2018) Julio A. Lamprea-Montealegre et al. DIABETES CARE
- Baseline characteristics and enrichment results from the SONAR trial
- (2018) Hiddo J.L. Heerspink et al. DIABETES OBESITY & METABOLISM
- DECLARE-TIMI 58: Participants’ baseline characteristics
- (2018) Itamar Raz et al. DIABETES OBESITY & METABOLISM
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review
- (2018) Karin Rådholm et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
- (2018) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease
- (2018) Akira Mima JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
- (2018) David Z.I. Cherney et al. KIDNEY INTERNATIONAL
- Does lower limb amputation concern all SGLT2 inhibitors?
- (2018) André J. Scheen Nature Reviews Endocrinology
- CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
- (2018) Hans-Joachim Anders et al. Nature Reviews Nephrology
- Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
- (2018) Claire C J Dekkers et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers
- (2018) Lili Tong et al. POSTGRADUATE MEDICINE
- Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review
- (2018) Keith C. Norris et al. BMC Nephrology
- Trends in Rates of Lower Extremity Amputation Among Patients With End-stage Renal Disease Who Receive Dialysis
- (2018) Douglas Franz et al. JAMA Internal Medicine
- Dulaglutide and renal protection in type 2 diabetes
- (2018) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Novel therapies for diabetic kidney disease
- (2018) David Z.I. Cherney et al. Kidney International Supplements
- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
- (2018) Fabrice Bonnet et al. DIABETES & METABOLISM
- Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis
- (2018) Ioannis Avgerinos et al. DIABETES OBESITY & METABOLISM
- Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016
- (2018) Yan Xie et al. KIDNEY INTERNATIONAL
- Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
- (2018) A.J. Scheen DIABETES & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel avenues for drug discovery in diabetic kidney disease
- (2017) Matthew D. Breyer et al. Expert Opinion on Drug Discovery
- Novel avenues for treating diabetic nephropathy: new investigational drugs
- (2017) Viviana Lacava et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Effects of blood-pressure-lowering treatment on outcome incidence in hypertension
- (2017) Costas Thomopoulos et al. JOURNAL OF HYPERTENSION
- Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
- (2017) Joshua J. Neumiller et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease
- (2017) Masayuki Yamanouchi et al. KIDNEY INTERNATIONAL
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database
- (2017) A. Perlman et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis
- (2017) P. Gargiulo et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Use of Surrogate Outcomes in Nephrology Research
- (2016) Joshua Samuels ADVANCES IN CHRONIC KIDNEY DISEASE
- Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
- (2016) Sanjay Kalra et al. ADVANCES IN THERAPY
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease
- (2016) Anjay Rastogi et al. CURRENT HYPERTENSION REPORTS
- SGLT2 Inhibitors and the Diabetic Kidney
- (2016) Paola Fioretto et al. DIABETES CARE
- Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy
- (2016) N. G. C. van der Sande et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials
- (2016) Katherine R. Tuttle et al. DIABETES OBESITY & METABOLISM
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
- (2016) Gemma Currie et al. BMC Nephrology
- Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses
- (2016) Mattias Brunström et al. BMJ-British Medical Journal
- Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses
- (2016) Ferrán Catalá-López et al. PLOS MEDICINE
- Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses
- (2016) Mattias Brunström et al. BMJ-British Medical Journal
- Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
- (2016) Seok Joon Shin et al. PLoS One
- Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2015) Ronan Roussel et al. ADVANCES IN THERAPY
- Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2015) André J. Scheen CLINICAL PHARMACOKINETICS
- Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
- (2015) Marko Škrtić et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Blood Pressure Lowering in Type 2 Diabetes
- (2015) Connor A. Emdin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis
- (2015) Suetonia C Palmer et al. LANCET
- Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
- (2015) Merlin C. Thomas et al. Nature Reviews Nephrology
- Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR
- (2015) Guideline development group et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
- (2015) Matthew R. Weir et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
- (2015) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade
- (2015) Maria Perez-Gomez et al. Journal of Clinical Medicine
- Diabetic Kidney Disease: A Report From an ADA Consensus Conference
- (2014) Katherine R. Tuttle et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
- (2014) Andrew S. Levey et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
- (2014) Josef Coresh et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Therapeutic approaches to diabetic nephropathy—beyond the RAS
- (2014) Beatriz Fernandez-Fernandez et al. Nature Reviews Nephrology
- Interpreting Treatment Effects From Clinical Trials in the Context of Real-World Risk Information
- (2014) Ann M. O’Hare et al. JAMA Internal Medicine
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease
- (2013) Regina Kunz et al. ANNALS OF INTERNAL MEDICINE
- Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
- (2013) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- The economic burden of progressive chronic kidney disease among patients with type 2 diabetes
- (2013) Suma Vupputuri et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- The effect of RAAS blockade on the progression of diabetic nephropathy
- (2013) Sara S. Roscioni et al. Nature Reviews Nephrology
- Animal models of chronic kidney disease: useful but not perfect
- (2013) G. J. Becker et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
- (2013) Linda F. Fried et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
- (2013) Dick de Zeeuw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis
- (2013) H.-Y. Wu et al. BMJ-British Medical Journal
- KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
- (2012) AMERICAN JOURNAL OF KIDNEY DISEASES
- Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes Mellitus
- (2012) Steven G. Coca et al. ARCHIVES OF INTERNAL MEDICINE
- Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR
- (2012) M. Rahman et al. Clinical Journal of the American Society of Nephrology
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Notice
- (2012) Kidney International Supplements
- Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
- (2011) E. Imai et al. DIABETOLOGIA
- Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis
- (2011) P. Vejakama et al. DIABETOLOGIA
- Stopping Renin-Angiotensin System Inhibitors in Chronic Kidney Disease: Predictors of Response
- (2011) Anderson Roman Gonçalves et al. NEPHRON CLINICAL PRACTICE
- Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes
- (2011) Hermann Haller et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial
- (2010) Kazuwa Nakao et al. HYPERTENSION RESEARCH
- Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial
- (2009) S. Zoungas et al. DIABETES CARE
- Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
- (2009) B. E. de Galan et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review
- (2008) Andrew S. Bomback et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Slowing Nephropathy Progression: Focus on Proteinuria Reduction
- (2008) G. L. Bakris Clinical Journal of the American Society of Nephrology
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now